ARTICLE | Financial News
Immunomedics proposes follow-on
February 22, 2013 2:05 AM UTC
Immunomedics Inc. (NASDAQ:IMMU) said late Thursday it is planning a follow-on underwritten by Oppenheimer and Cowen. Immunomedics' epratuzumab is in Phase II testing to treat acute lymphoblastic leuke...